The Current Ratio as of October 2024 (TTM) for Lyell Immunopharma, Inc. (LYEL) is 16.19

According to Lyell Immunopharma, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 16.19. This represents a change of -1.16% compared to the average of 16.38 of the last 4 quarters.

Lyell Immunopharma, Inc. (LYEL) Historical Current Ratio (quarterly & annually)

How has LYEL Current Ratio performed in the past?

The mean historical Current Ratio of Lyell Immunopharma, Inc. over the last ten years is 15.91. The current 16.19 Current Ratio has changed 10.07% with respect to the historical average. Over the past ten years (40 quarters), LYEL's Current Ratio was at its highest in in the March 2023 quarter at 20.27. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Lyell Immunopharma, Inc. (LYEL) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Lyell Immunopharma, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Lyell Immunopharma, Inc. (LYEL) Average Current Ratio

How has LYEL Current Ratio performed in the past?

The current Current Ratio of Lyell Immunopharma, Inc. (LYEL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Lyell Immunopharma, Inc. (LYEL) Current Ratio vs. Peers

How is LYEL’s Current Ratio compared to its peers?

Lyell Immunopharma, Inc.’s Current Ratio is less than Cullinan Oncology, Inc. (28.87), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Theseus Pharmaceuticals, Inc. (29.93), greater than Revolution Medicines, Inc. (15.42), greater than Nkarta, Inc. (15.91), greater than Generation Bio Co. (7.42), greater than Sana Biotechnology, Inc. (5.20), greater than Nuvation Bio Inc. (11.49), greater than Century Therapeutics, Inc. (10.62), greater than Shattuck Labs, Inc. (7.62), greater than Crinetics Pharmaceuticals, Inc. (16.09), greater than Inhibrx Biosciences, Inc. (6.20), greater than Merus N.V. (9.97), greater than Kronos Bio, Inc. (8.49), less than Edgewise Therapeutics, Inc. (30.24), greater than C4 Therapeutics, Inc. (5.09), greater than Mineralys Therapeutics, Inc. (11.20),

Build a custom stock screener for Lyell Immunopharma, Inc. (LYEL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lyell Immunopharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lyell Immunopharma, Inc. (LYEL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lyell Immunopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.